Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada – Updated August 6, 2013 Calcitonin is a hormone found naturally in our bodies. A synthetic form […]

Board of Directors Jeannette Briggs Chair | Oakville, ON Jeannette has more than 25 years of experience working in the energy sector.  She has held a wide-range of jobs within […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]

Donate Today Your gift will immediately help to educate, empower, and support individuals and communities on bone health and in the risk-reduction and treatment of osteoporosis. Donate Cook With OC […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]